Conference Coverage

ART traces in donor samples show risk to blood supply


 

REPORTING FROM AABB 2019

Mitigation Efforts

The National Heart, Lung, and Blood Institute is supporting a 7-year research project to study the potential impact of antiretroviral therapy and PrEP in the United States and Brazil under the Recipient Epidemiology and Donor Evaluation Study-IV-Pediatric (REDS-IV-P) project.

In addition, an AABB task force has drafted new questions for the donor health questionnaire intended to focus the attention of potential donors on PrEP, postexposure prophylaxis (PEP), and antiretroviral therapy.

In addition to asking about the use of medications on the deferral list, the proposed additions would ask, “In the past 16 weeks, have you taken any medication to prevent an HIV infection?” and “Have you EVER taken any medication to treat an HIV infection?”

TTIMS is supported by the U.S. Food and Drug Administration, NHLBI, and the Office of the Assistant Secretary for Health. Dr. Custer and all coinvestigators reported having no relevant disclosures.

SOURCE: : wit AABB 2019. Abstract PL5-MN4-32

Pages

Recommended Reading

Denmark reinstates ID NAT screening for blood donations
MDedge Infectious Disease
Zika virus testing shows low incidence in donor blood outside of high-infection areas
MDedge Infectious Disease
Zika RNA persists in blood components after clearance from plasma
MDedge Infectious Disease
FDA approves tests to screen for tickborne parasite in blood supply
MDedge Infectious Disease
Screening blood donations for Zika proved costly, low yield
MDedge Infectious Disease
Blood type A linked to more-severe diarrhea
MDedge Infectious Disease
FDA recommends pooled Zika testing of blood donations
MDedge Infectious Disease
Need blood STAT? Call for a drone
MDedge Infectious Disease
FDA committee advises status quo for blood supply Zika testing
MDedge Infectious Disease
FDA examines changing donation policies for men who have sex with men
MDedge Infectious Disease